Skip to main content

Table 1 Patient characteristics (n = 12)

From: Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study

Median age, yrs. (range) 66 (48 – 78)
 Gender  
  Male/Female 9/3
 PS  
  0/1 3/9
 Histology  
  Adeno/Large/Other 7/1/4
 Clinical Stage  
  IIIB/IV 3/9
 Smoking History  
  Current/Ex/Never 1/8/3
 EGFR mutation  
  Positive/Negative 2/10
 Best response to prior chemo  
  PR/SD/PD/NE 3/5/3/1